A Randomised Controlled Trial to Assess the Immunogenicity, Safety and Reactogenicity of a Second Standard Monovalent (Ancestral) or Bivalent Omicron-specific COVID-19 Vaccine Booster Dose (Pfizer-BioNTech or Moderna) in Healthy Adults in Australia.
Latest Information Update: 19 Mar 2024
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 07 Dec 2022 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.
- 07 Dec 2022 Planned initiation date changed from 10 Oct 2022 to 28 Feb 2023.
- 07 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.